Anavex Beyond

Anavex’s lead drug candidate ANAVEX 2-73 - targeting Alzheimer’s Disease - is in Phase 1 clinical trials. The company has also initiated scale-up manufacturing of ANAVEX 1-41 targeting a range of important CNS disorders, including depression and Alzheimer’s Disease. Three more of its compounds (for malignant melanoma, prostatic cancer and epilepsy) are expected to reach final preclinical stages in the near term.

Other early-stage preclinical research (see diagram) involves drug candidates that target diseases like depression, neuropathic pain and various types of cancer.

The company has over 30 novel drug candidates and is open to discussions with industrial partners.

© 2007-2014 Anavex Life Sciences Corp. - All Rights Reserved.
ANAVEX 1079 ANAVEX 1005 ANAVEX 1007 ANAVEX 1519 ANAVEX 1066 ANAVEX 2-73 ANAVEX 2-73 ANAVEX 2-73 ANAVEX 19-144 ANAVEX 19-144 ANAVEX 19-144 ANAVEX 1-41 ANAVEX 1-41 ANAVEX 1-41